Lu SM, et al. - Researchers report their experience and outcomes with a definitive concurrent chemoradiation regimen ie, triweekly carboplatin (tCb) area under the curve (AUC) 5 with concurrent radiotherapy in patients with locally advanced laryngeal carcinoma (LALC), given tCb AUC 5 was adopted as an alternative to high-dose cisplatin (100 mg/m²) for select patients receiving definitive concurrent chemoradiation for LALC in 2003 at authors' institution. With tolerable toxicity, acceptable outcomes were offered by tCb AUC 5 with concurrent radiotherapy in patients with LALC who were suboptimal candidates for high-dose cisplatin.